Can azathioprine be initiated for ulcerative colitis at 7 weeks of pregnancy?

Can Azathioprine Be Initiated for UC at 7 Weeks of Pregnancy?

Yes, azathioprine can be initiated for ulcerative colitis at 7 weeks of pregnancy if the disease is active and requires treatment, though this decision requires careful consideration of disease severity versus alternative therapies.

Clinical Decision Framework

The Toronto Consensus Guidelines provide clear direction: pregnant women with IBD who have a disease flare on optimal 5-ASA or thiopurine maintenance therapy should be treated with systemic corticosteroids or anti-TNF therapy to induce symptomatic remission 1. Notably, the guidelines specifically recommend continuation of thiopurine therapy throughout pregnancy for women already on maintenance 1, but do not explicitly address initiation during pregnancy.

The 2025 Global Consensus Statement clarifies this gap: women with IBD who are pregnant and with active disease should start or optimize the same appropriate therapies as in nonpregnant patients, except for thiopurines, methotrexate, Janus kinase inhibitors, and sphingosine 1 receptor modulators 2. This represents a more cautious stance on initiating thiopurines during pregnancy.

Recommended Treatment Algorithm at 7 Weeks Gestation

First-Line Approach:

• Optimize 5-ASA therapy (oral and rectal combination) for mild-to-moderate UC flares 1
• Initiate systemic corticosteroids for moderate-to-severe disease activity 1

Second-Line Approach:

• Initiate anti-TNF therapy for corticosteroid-resistant disease or as an alternative to steroids 1
• If thiopurine-naïve and starting anti-TNF, use anti-TNF monotherapy rather than combination therapy 1

When to Consider Azathioprine Initiation:

Azathioprine initiation at 7 weeks may be appropriate when:

• The patient has failed 5-ASA optimization
• Corticosteroids are contraindicated or have failed previously
• Anti-TNF therapy is not accessible or contraindicated
• The disease severity threatens maternal health more than potential fetal risks

Critical Safety Considerations

FDA Drug Label Warnings 3:

The FDA label states that azathioprine can cause fetal harm when administered to a pregnant woman and should not be given during pregnancy without careful weighing of risk versus benefit. The label notes:

• Teratogenic in rabbits and mice at human-equivalent doses
• Skeletal malformations and visceral anomalies documented in animal studies
• Limited immunologic abnormalities reported in some infants born to mothers on azathioprine
• Postmarketing cases of intrahepatic cholestasis of pregnancy (ICP) have been reported; discontinue if ICP develops 3

Research Evidence on Pregnancy Outcomes:

The evidence shows conflicting results:

Concerning findings:

• A Swedish registry study (476 pregnancies) found a trend toward increased congenital malformations (6.2% vs 4.7%; adjusted OR 1.41,95% CI 0.98-2.04) and a significant association with ventricular/atrial septal defects (adjusted OR 3.18,95% CI 1.45-6.04) 4
• Increased risk of preterm birth, low birth weight, and small for gestational age 4, 5

Reassuring findings:

• Multiple smaller studies showed no increased congenital abnormalities 6, 7, 8
• One study of 19 exposed births found no association with preterm birth, low birth weight, or congenital anomalies 8

Practical Management if Azathioprine is Initiated

Monitoring Requirements 3:

• Complete blood counts with platelets weekly during the first month
• Twice monthly for months 2-3
• Monthly thereafter or more frequently if needed
• Liver enzymes to monitor for intrahepatic cholestasis of pregnancy 3
• Consider TPMT and NUDT15 genotyping before initiation to identify patients at risk for severe myelotoxicity 3

Dose Adjustments:

• Patients with heterozygous TPMT or NUDT15 deficiency require reduced dosing 3
• Consider alternative therapy in homozygous deficiency 3

Multidisciplinary Care:

• Consultation with high-risk obstetrics is mandatory 1
• Gastroenterologist management throughout pregnancy 1

Common Pitfalls to Avoid

1. Do not delay treatment of active UC during pregnancy—uncontrolled disease poses greater risks to mother and fetus than most medications 1

2. Do not confuse continuation with initiation—the evidence strongly supports continuing azathioprine in women already on maintenance, but initiation during pregnancy requires more careful consideration

3. Do not use azathioprine as first-line therapy when safer alternatives (optimized 5-ASA, corticosteroids, or anti-TNF) are available and appropriate

4. Do not forget to monitor for intrahepatic cholestasis of pregnancy—this is a specific pregnancy-related complication that requires azathioprine discontinuation 3

5. Do not combine with xanthine oxidase inhibitors (allopurinol, febuxostat) without dose reduction to 1/3-1/4 usual dose 3

The Bottom Line

While azathioprine can be initiated at 7 weeks of pregnancy for active UC, it should generally be reserved for situations where first-line therapies (optimized 5-ASA, corticosteroids, or anti-TNF) are inadequate, contraindicated, or inaccessible. The 2025 Global Consensus suggests avoiding thiopurine initiation during pregnancy when possible 2, but the Toronto Consensus supports treating active disease aggressively to prevent worse maternal and fetal outcomes 1. The risk of uncontrolled UC during pregnancy typically outweighs the potential risks of azathioprine, but safer alternatives should be prioritized first.